IL HB1443 | 2025-2026 | 104th General Assembly
Status
Sponsorship: Partisan Bill (Democrat 30)
Status: Introduced on January 17 2025 - 25% progression, died in committee
Action: 2026-04-17 - House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee
Pending: House Rules Committee
Text: Latest bill text (Engrossed) [HTML]
Status: Introduced on January 17 2025 - 25% progression, died in committee
Action: 2026-04-17 - House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee
Pending: House Rules Committee
Text: Latest bill text (Engrossed) [HTML]
Summary
Reinserts the provisions of the introduced bill with the following changes. Makes changes to defined terms. Replaces references to the Health Care Availability and Access Board, the Health Care Availability and Access Stakeholder Council, and the Health Care Availability and Access Board Fund to the Prescription Drug Affordability Board, the Prescription Drug Affordability Stakeholder Council, and the Prescription Drug Affordability Board Fund. Requires Prescription Drug Affordability Board membership to also include individuals with expertise in the practice of pharmacy. Includes reimbursements from health benefit plans in provisions concerning upper payment limits for payor reimbursements. Requires the Board to maintain financial records and accounts in accordance with generally accepted governmental accounting principles. Provides that the Board shall be deemed a public body for purposes of the Freedom of Information Act and the Open Meetings Act; all records of the Board, including meeting minutes, cost review records, and correspondence, shall be public records subject to disclosure in accordance with the Freedom of Information Act, except as otherwise provided by law; and meetings of the Board shall be open to the public in accordance with the Open Meetings Act. Requires the Board to establish an operational plan for distribution and access to a drug with an upper payment limit before the Board reviews specific drugs for affordability and establishes any upper payment limits. Provides that the Board shall prioritize establishing and implementing upper payment limits for the 10 prescription drug products with a Medicare Maximum Fair Price that went into effect in 2026 before proceeding with upper payment limits on other prescription drug products with a Medicare Maximum Fair Price or affordability reviews for any other prescription drug products. Adds more items to the list of information that may be included to conduct an affordability review. Provides that the Board may suspend an upper payment limit if it determines that there is a shortage of the drug in the State unless the Board determines that the shortage was caused by a manufacturer or its agent. Changes expertise requirements for membership of the Prescription Drug Affordability Stakeholder Council. Establishes specified exemptions for the Department of Healthcare and Family Services and other State departments in provisions concerning protections and other Board considerations. Provides that any upper payment limit established by the Board shall not apply to prescription drug products purchased by the Department of Healthcare and Family Services for the medical assistance program under Article V of the Illinois Public Aid Code or to a health care plan serving Medicaid populations that provides, arranges for, pays for, or reimburses the cost of any health care service for persons who are enrolled under the medical assistance program under Article V of the Illinois Public Aid Code unless, after consultation with and approval of the Director of Healthcare and Family Services, it is determined that the upper payment limit would reduce costs to the State. Provides that, if a prescription drug product subject to an upper payment limit established under the Act is intended to be made available for purchase by pharmacies, distributors, or wholesalers licensed in the State, it shall be available at a price that does not exceed the upper payment limit (rather than a wholesaler or distributor shall make any prescription drug product that is subject to an upper payment limit established under the Act available for purchase by pharmacies licensed in this State at a price that does not exceed the established upper payment limit), and, if a wholesaler or distributor acquires a prescription drug product subject to an upper payment limit at a price that exceeds the upper payment limit, the wholesaler or distributor is entitled to a chargeback or rebate equal to the difference between the price and the upper payment limit from the entity that sold the product to the wholesaler or distributor. Changes the required reporting date for the Board concerning the operation of the generic drug market in the United States to June 1, 2027 (rather than June 1, 2025). Requires the Board to notify the General Assembly if 5 years have passed without any litigation hindering Board operations. Provides that the Act is repealed 5 years after the effective date of the Act. Makes other changes. Effective 180 days after becoming law.
Title
HEALTH CARE AVAILABILITY
Sponsors
History
| Date | Chamber | Action |
|---|---|---|
| 2026-04-17 | House | House Floor Amendment No. 3 Rule 19(c) / Re-referred to Rules Committee |
| 2026-04-17 | House | House Floor Amendment No. 2 Rule 19(c) / Re-referred to Rules Committee |
| 2026-04-17 | House | House Floor Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee |
| 2026-04-17 | House | Rule 19(a) / Re-referred to Rules Committee |
| 2026-04-16 | House | Placed on Calendar Order of 3rd Reading - Standard Debate |
| 2026-04-16 | House | Chair Rules Standard Debate |
| 2026-04-16 | House | Placed on Calendar Order of 3rd Reading - Short Debate |
| 2026-04-16 | House | Removed Co-Sponsor Rep. Will Guzzardi |
| 2026-04-16 | House | Added Chief Co-Sponsor Rep. Will Guzzardi |
| 2026-04-16 | House | Added Co-Sponsor Rep. Yolonda Morris |
| 2026-04-16 | House | House Floor Amendment No. 4 Adopted |
| 2026-04-16 | House | State Debt Impact Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Racial Impact Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | State Mandates Fiscal Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Pension Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Land Conveyance Appraisal Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Judicial Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Housing Affordability Impact Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Home Rule Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Fiscal Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Correctional Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | Balanced Budget Note Requested - Withdrawn by Rep. Nabeela Syed |
| 2026-04-16 | House | House Floor Amendment No. 4 Recommends Be Adopted Health Care Availability & Accessibility Committee; 009-005-000 |
| 2026-04-16 | House | House Floor Amendment No. 4 Rules Refers to Health Care Availability & Accessibility Committee |
| 2026-04-15 | House | House Floor Amendment No. 4 Referred to Rules Committee |
| 2026-04-15 | House | House Floor Amendment No. 4 Filed with Clerk by Rep. Nabeela Syed |
| 2026-04-15 | House | House Floor Amendment No. 3 Rules Refers to Health Care Availability & Accessibility Committee |
| 2026-04-15 | House | House Floor Amendment No. 3 Referred to Rules Committee |
| 2026-04-15 | House | House Floor Amendment No. 3 Filed with Clerk by Rep. Nabeela Syed |
| 2026-04-14 | House | House Floor Amendment No. 2 Rules Refers to Health Care Availability & Accessibility Committee |
| 2026-04-14 | House | House Floor Amendment No. 2 Referred to Rules Committee |
| 2026-04-14 | House | House Floor Amendment No. 2 Filed with Clerk by Rep. Nabeela Syed |
| 2026-04-10 | House | Fiscal Note Filed |
| 2026-04-10 | House | Held on Calendar Order of Second Reading - Short Debate |
| 2026-04-10 | House | Second Reading - Short Debate |
| 2026-04-08 | House | House Floor Amendment No. 1 Rules Refers to Health Care Availability & Accessibility Committee |
| 2026-04-08 | House | House Floor Amendment No. 1 Referred to Rules Committee |
| 2026-04-08 | House | House Floor Amendment No. 1 Filed with Clerk by Rep. Nabeela Syed |
| 2026-04-07 | House | State Mandates Fiscal Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | State Debt Impact Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Racial Impact Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Pension Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Land Conveyance Appraisal Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Judicial Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Housing Affordability Impact Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Home Rule Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Fiscal Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Correctional Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Balanced Budget Note Requested by Rep. Nabeela Syed |
| 2026-04-07 | House | Added Co-Sponsor Rep. Emanuel "Chris" Welch |
| 2026-04-07 | House | Added Co-Sponsor Rep. Laura Faver Dias |
| 2026-03-25 | House | Placed on Calendar 2nd Reading - Short Debate |
| 2026-03-24 | House | Do Pass / Short Debate Health Care Availability & Accessibility Committee; 008-004-000 |
| 2026-03-12 | House | Assigned to Health Care Availability & Accessibility Committee |
| 2026-02-20 | House | Added Co-Sponsor Rep. Rita Mayfield |
| 2026-02-05 | House | Added Co-Sponsor Rep. Lisa Davis |
| 2026-02-05 | House | Added Co-Sponsor Rep. Michael Crawford |
| 2026-02-03 | House | Added Co-Sponsor Rep. Kimberly Du Buclet |
| 2025-05-14 | House | Added Co-Sponsor Rep. Joyce Mason |
| 2025-04-29 | House | Added Co-Sponsor Rep. La Shawn K. Ford |
| 2025-03-21 | House | Rule 19(a) / Re-referred to Rules Committee |
| 2025-03-13 | House | Added Co-Sponsor Rep. Dagmara Avelar |
| 2025-03-13 | House | Added Co-Sponsor Rep. Maura Hirschauer |
| 2025-03-07 | House | Added Co-Sponsor Rep. Anna Moeller |
| 2025-03-05 | House | Added Co-Sponsor Rep. Anne Stava |
| 2025-03-04 | House | Added Co-Sponsor Rep. Debbie Meyers-Martin |
| 2025-02-26 | House | Added Co-Sponsor Rep. Suzanne M. Ness |
| 2025-02-26 | House | Added Co-Sponsor Rep. Camille Y. Lilly |
| 2025-02-25 | House | To Prescription Drug Affordability Board |
| 2025-02-25 | House | Added Co-Sponsor Rep. Gregg Johnson |
| 2025-02-25 | House | Added Co-Sponsor Rep. Kevin John Olickal |
| 2025-02-25 | House | Added Co-Sponsor Rep. Norma Hernandez |
| 2025-02-19 | House | Added Co-Sponsor Rep. Nicolle Grasse |
| 2025-02-19 | House | Added Co-Sponsor Rep. Michelle Mussman |
| 2025-02-18 | House | Added Co-Sponsor Rep. Will Guzzardi |
| 2025-02-18 | House | Assigned to Health Care Availability & Accessibility Committee |
| 2025-02-18 | House | Added Co-Sponsor Rep. Kelly M. Cassidy |
| 2025-02-13 | House | Added Co-Sponsor Rep. Mary Beth Canty |
| 2025-02-13 | House | Added Co-Sponsor Rep. Abdelnasser Rashid |
| 2025-02-11 | House | Added Co-Sponsor Rep. Theresa Mah |
| 2025-02-04 | House | Added Co-Sponsor Rep. Janet Yang Rohr |
| 2025-02-04 | House | Added Co-Sponsor Rep. Diane Blair-Sherlock |
| 2025-02-03 | House | Added Co-Sponsor Rep. Katie Stuart |
| 2025-01-28 | House | Referred to Rules Committee |
| 2025-01-28 | House | First Reading |
| 2025-01-17 | House | Filed with the Clerk by Rep. Nabeela Syed |
